https://www.selleckchem.com/products/stattic.html
001). Through 180 days, 17 of 22 NAT+ recipients (77%) had a repeat rejection biopsy vs 12 of 28 NAT- recipients (43%) (p = 0.02). NAT+ biopsies demonstrated disparity of ACR distribution negative, low-grade, and high-grade ACR in 84%, 12%, and 4%, respectively, vs 96%, 3%, and 1%, respectively, in the NAT- group (p = 0.03). The median time to first event was 26 (interquartile range [IQR] 8-45) in the NAT+ group vs 65 (IQR 44-84) days in the NAT-. Time to first event risk model revealed that NAT+ recipients had a significantly higher ra
Like
Comment
Share
